{"id":249897,"date":"2023-05-31T00:00:00","date_gmt":"2023-05-31T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidmd0086-biopharma-osteoporosis-epidemiology-asia-pacific\/"},"modified":"2026-03-31T10:33:12","modified_gmt":"2026-03-31T10:33:12","slug":"epidmd0086-biopharma-osteoporosis-epidemiology-asia-pacific","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidmd0086-biopharma-osteoporosis-epidemiology-asia-pacific\/","title":{"rendered":"Osteoporosis &#8211; Epidemiology &#8211; Asia-Pacific"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of osteoporosis (<abbr title=\"osteoporosis\">OSP<\/abbr>) comprises epidemiological estimates of key patient populations in 45\u00a0countries worldwide. We report the prevalence of <abbr title=\"osteoporosis\">OSP<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"osteoporosis\">OSP<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"osteoporosis\">OSP<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>Clarivate Epidemiology forecasts the following <abbr title=\"osteoporosis\">OSP<\/abbr> patient population:<\/p>\n<ul class=\"round-bullets\">\n<li>Total prevalent cases by the World Health Organization (<abbr title=\"World Health Organization\">WHO<\/abbr>) definition.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-249897","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-osteoporosis","biopharma-product-epidemiology","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249897","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249897\/revisions"}],"predecessor-version":[{"id":281532,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249897\/revisions\/281532"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=249897"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}